• Теги
    • избранные теги
    • Компании155
      • Показать ещё
      • Показать ещё
      Страны / Регионы75
      • Показать ещё
      Международные организации3
11 января, 02:25

Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

Выбор редакции
09 января, 16:11

Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

08 декабря 2016, 21:25

СМИ сообщили об эксперименте властей по возврату денег за неэффективное лечение

Фармкомпании могут получать деньги только за эффективные препараты. Об этом сообщает РБК со ссылкой на копию распоряжения вице-премьера Игоря Шувалова. Шувалов...

Выбор редакции
05 декабря 2016, 17:10

Alnylam Reports Positive Data on Fitusiran, Givosiran

Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

Выбор редакции
15 ноября 2016, 16:53

Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.

Alnylam Pharmaceuticals, Inc. (ALNY) announced that Genzyme, the specialty care global business unit of Sanofi (SNY), has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.

Выбор редакции
Выбор редакции
03 ноября 2016, 15:45

Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up

Alnylam (ALNY) reported a loss of $1.21 per share in the third quarter of 2016 on revenues of $13.7 million.

31 октября 2016, 16:14

Sanofi (SNY) Beats Earnings, Revenues Rise Y/Y; Ups View

Sanofi (SNY) reported third-quarter 2016 business earnings of $1.00 per American Depositary Share, which beat the Zacks Consensus Estimate of 86 cents by 16.28%.

28 октября 2016, 17:21

BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus

BioMarin Pharmaceutical (BMRN) reported a loss of 18 cents per share in the third quarter of 2016, narrower than the year-ago loss of 44 cents.

08 сентября 2016, 16:42

Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1

Alnylam Pharmaceuticals, Inc. (ALNY) announced positive interim results from an ongoing phase I study, evaluating its pipeline candidate, ALN-AS1.

05 августа 2016, 18:34

BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped

BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.

02 августа 2016, 00:19

Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y

Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.

07 июля 2016, 17:09

Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan

Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.

Выбор редакции
05 мая 2016, 17:20

Ionis Incurs Wider-than-Expected Loss in Q1, Stock Down

Ionis Pharmaceuticals (IONS) reported a wider-than-expected first-quarter 2016 loss of 52 cents; revenues plunged year over year.

03 мая 2016, 17:38

Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1

Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.

29 апреля 2016, 20:32

BioMarin (BMRN) Reports Narrower-than-Expected Q1 Loss

BioMarin (BMRN) reported a loss of 35 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimates of a loss of 85 cents.